Skip to content
01Investment Thesis

Where Ventures may look, and what it would need to see first.

KeyMaker Ventures is being designed to back healthcare companies with evidence of buyer need and a clear path to adoption. The categories below describe the proposed focus of a future investment arm — not an active pipeline.

Proposed focus · No pipeline, company, or deal is active

Proposed focus

Three categories may be considered.

Each category would be evaluated on its own evidence. Nothing here represents a commitment, allocation, or existing relationship.

01

Studio spinouts

May consider

Companies formed from validated problem areas, ideally with a design partner, clear buyer, and defined product and operating plan.

02

Outside healthcare companies

May consider

Select companies encountered through Services, referrals, or other appropriate channels that have buyer traction and a fit with KeyMaker's delivery and market-access capabilities.

03

Follow-on opportunities

May consider

Potential additional support for companies that meet agreed milestones, subject to a separate investment decision and available capital.

What we look for

Evidence a company can carry.

These are the questions a proposed Ventures review would ask. They are diligence expectations, not eligibility criteria.

  • 01

    Evidence that a buyer has the problem.

  • 02

    An identifiable purchaser and plausible budget path.

  • 03

    A product or solution that can be evaluated against defined requirements.

  • 04

    Access to users or a design partner.

  • 05

    A credible implementation and adoption plan.

  • 06

    A capable team or realistic founder-recruitment plan.

  • 07

    A viable regulatory, privacy, and security path.

  • 08

    Economics that justify the next stage of capital and work.

What requires more review

Some questions sit outside a first conversation.

These areas would require specialist input, documented rights, and counsel review before any decision.

No product type is categorically eligible for investment. Each opportunity would be reviewed on its own evidence, and several of these questions may remain unresolved.

  • 01

    Products involving diagnosis, treatment claims, medical devices, drugs, reimbursement, or clinical decision-making.

  • 02

    Concepts that rely on data or intellectual property from another organization.

  • 03

    Opportunities with unresolved conflicts or unclear ownership.

  • 04

    Companies without an identified buyer, budget path, or feasible operating plan.

Continue

See how diligence would be organized.

The evaluation page sets out illustrative diligence areas across buyer evidence, product, team, healthcare readiness, and commercial path.